Implementation of Modern Therapeutic Drug Monitoring and Lipidomics Approaches in Clinical Practice: A Case Study with Colistin Treatment

Autor: Ivana Gerhardtova, Ivana Cizmarova, Timotej Jankech, Dominika Olesova, Josef Jampilek, Vojtech Parrak, Kristina Nemergutova, Ladislav Sopko, Juraj Piestansky, Andrej Kovac

Publikováno v: Pharmaceuticals, Vol 17, Iss 6, p 753 (2024)

Nowadays, lipidomics plays a crucial role in the investigation of novel biomarkers of various diseases. Its implementation into the field of clinical analysis led to the identification of specific lipids and/or significant changes in their plasma lev

Externí odkaz: https://doaj.org/article/54a097b7e4d64de8af3d6ab815d58a3d

Monoclonal antibodies targeting two immunodominant epitopes on the Spike protein neutralize emerging SARS-CoV-2 variants of concern

Autor: Branislav Kovacech, Lubica Fialova, Peter Filipcik, Rostislav Skrabana, Monika Zilkova, Natalia Paulenka-Ivanovova, Andrej Kovac, Denisa Palova, Gabriela Paulikova Rolkova, Katarina Tomkova, Natalia Turic Csokova, Karina Markova, Michaela Skrabanova, Kristina Sinska, Neha Basheer, Petra Majerova, Jozef Hanes, Vojtech Parrak, Michal Prcina, Ondrej Cehlar, Martin Cente, Juraj Piestansky, Michal Fresser, Michal Novak, Monika Slavikova, Kristina Borsova, Viktoria Cabanova, Bronislava Brejova, Tomas Vinař, Jozef Nosek, Boris Klempa, Ludek Eyer, Vaclav Hönig, Martin Palus, Daniel Ruzek, Tereza Vyhlidalova, Petra Strakova, Blanka Mrazkova, Dagmar Zudova, Gizela Koubkova, Vendula Novosadova, Jan Prochazka, Radislav Sedlacek, Norbert Zilka, Eva Kontsekova

Publikováno v: EBioMedicine, Vol 76, Iss , Pp 103818- (2022)

Summary: Background: The emergence of new SARS-CoV-2 variants of concern B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma) and B.1.617.2 (Delta) that harbor mutations in the viral S protein raised concern about activity of current vaccines and therapeutic

Externí odkaz: https://doaj.org/article/d503988bb92a4f8ca2f39b041da95550

Profiling of Amino Acids in Urine Samples of Patients Suffering from Inflammatory Bowel Disease by Capillary Electrophoresis-Mass Spectrometry

Autor: Juraj Piestansky, Dominika Olesova, Jaroslav Galba, Katarina Marakova, Vojtech Parrak, Peter Secnik, Branislav Kovacech, Andrej Kovac, Zuzana Zelinkova, Peter Mikus

Publikováno v: Molecules, Vol 24, Iss 18, p 3345 (2019)

Urine represents a convenient biofluid for metabolomic studies due to its noninvasive collection and richness in metabolites. Here, amino acids are valuable biomarkers for their ability to reflect imbalances of different biochemical pathways. An impa

Externí odkaz: https://doaj.org/article/d0a824cd684041708f1346a761226a22

ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer’s disease

Autor: Duygu Tosun, Jozef Hanes, Branislav Kovacech, Tomas Hromadka, Lutz Froelich, Stanislav Katina, Lubica Fialova, Michal Prcina, Norbert Zilka, Andrej Kovac, Reinhold Schmidt, Eva Kontsekova, Martin Rakusa, Martin Cente, Carmen Prenn-Gologranc, Milica G. Kramberger, Stanislav Sutovsky, Peter Koson, Markus Otto, Stefan Ropele, Petr Novak, John Harrison, Michal Novak, Roman Sivak, Juraj Piestansky, Matej Ondrus, Jaroslav Galba, Miroslav Smisek, Maria Samcova, Eva Stevens, Jakub Hort, Bengt Winblad, Philip Scheltens, Vojtech Parrak, Peter Filipcik, Michal Fresser, Natalia Paulenka-Ivanovova

Publikováno v: Nature Aging, 1(6), 521-534. Springer
Novak, P, Kovacech, B, Katina, S, Schmidt, R, Scheltens, P, Kontsekova, E, Ropele, S, Fialova, L, Kramberger, M, Paulenka-Ivanovova, N, Smisek, M, Hanes, J, Stevens, E, Kovac, A, Sutovsky, S, Parrak, V, Koson, P, Prcina, M, Galba, J, Cente, M, Hromadka, T, Filipcik, P, Piestansky, J, Samcova, M, Prenn-Gologranc, C, Sivak, R, Froelich, L, Fresser, M, Rakusa, M, Harrison, J, Hort, J, Otto, M, Tosun, D, Ondrus, M, Winblad, B, Novak, M & Zilka, N 2021, ' ADAMANT : a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer’s disease ', Nature Aging, vol. 1, no. 6, pp. 521-534 . https://doi.org/10.1038/s43587-021-00070-2

Alzheimer’s disease (AD) pathology is partly characterized by accumulation of aberrant forms of tau protein. Here we report the results of ADAMANT, a 24-month double-blinded, parallel-arm, randomized phase 2 multicenter placebo-controlled trial of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f9207a075a751b59f0b0c380b710aaf1
https://research.vumc.nl/en/publications/61abe2cc-82ad-4ac3-93be-d1cbc548881b

Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial

Autor: Rostislav Skrabana, Vojtech Parrak, Zuzana Vince-Kazmerova, Stefan Ropele, Norbert Zilka, Michal Prcina, Michael Rainer, Lubica Fialova, Eva Kontsekova, Branislav Kovacech, Petr Novak, Miroslav Smisek, Roman Sivak, Peter Dal-Bianco, Stanislav Katina, Matej Ondrus, Wolfgang Staffen, Michal Novak, Martin Brunner, Reinhold Schmidt, Bengt Winblad

Publikováno v: The Lancet Neurology. 16:123-134

Summary Background Neurofibrillary pathology composed of tau protein is a main correlate of cognitive impairment in patients with Alzheimer's disease. Immunotherapy targeting pathological tau proteins is therefore a promising strategy for disease-mod

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::815d65fd312c8c400d5edc2b36cae44b
https://doi.org/10.1016/s1474-4422(16)30331-3